Ending Inflammation Rather Than Suppressing It: Resolution and Natural Compounds

1. Resolution: Resolvins, Protectins, Macrophage Switching

Evidence-based: Omega-3 fatty acids (EPA/DHA) increase the concentration of pro-resolving mediators such as 18-HEPE, 17-HDHA, and resolvins in humans. In chronic inflammation (e.g., IBD), symptoms and quality of life improved 2.

Plausible Resolvins and protectins are derived from EPA/DHA through enzymes such as 15-LOX. Animal models demonstrate that this mechanism accelerates tissue regeneration 1.

resolving

phenotype may be the key to why omega-3 fatty acids are effective in autoimmune diseases (e.g., psoriasis, RA) 6. It remains to be tested whether combining them with other resolvin precursors (e.g., humic acid complexes) further enhances the synthesis of these mediators.

Substances involved in this link: Omega-3 fatty acids · Chronic inflammation

2. NF-κB, COX-2, and Classical Inhibition

Plausible NF-κB activates genes for COX-2, IL-6, and TNF-α. Animal models show that these mechanisms reduce fibrosis and steatosis in the liver 3.

Hypothesis The dual inhibition of NF-κB and COX-2 could explain why curcumin/Boswellia are more effective in chronic inflammation (e.g., IBD) than selective COX inhibitors 7. It remains unclear whether humic acid complexes modulate these pathways synergistically—perhaps by binding to NF-κB dimers.

Substances involved in this link: Turmeric and Curcumin · Frankincense (Boswellia) · Ginger · Quercetin

3. Human Biomarkers: CRP, IL-6, TNF

Ginger reduced IL-6/TNF-α in diabetics 5.

Plausible CRP correlates with NF-κB activity and COX-2 expression. Omega-3 fatty acids suppress the gene expression of pro-inflammatory cytokines in immune cells 4.

Hypothesis The simultaneous reduction of CRP, IL-6, and TNF-α suggests systemic dampening of the inflammatory cascade. However, whether this results from resolution (e.g., via resolvins) or mere inhibition would need to be clarified by measuring pro-resolving mediators (e.g., 17-HDHA).

Substances involved in this link: Omega-3 fatty acids · Turmeric and Curcumin · Frankincense (Boswellia) · Ginger · Black Cumin (Nigella sativa)

4. From Biomarkers to Clinical Outcomes: Joints, Gut, Skin

Evidence-based: Omega-3 fatty acids reduced the risk of autoimmune diseases (RA, psoriasis) by 15–22% in a large study 6.

Plausible The effect on joints correlates with decreasing inflammatory markers (CRP, PGE₂). In IBD (e.g., ulcerative colitis), curcumin induced remissions, while Boswellia was as effective as mesalazine 7. Animal models show that resolvins promote intestinal epithelial regeneration 1.

Hypothesis The clinical effects (joints, gut, skin) may result from a combination of inflammation inhibition (NF-κB/COX-2) and active resolution (resolvins). It remains to be tested whether humic acid complexes—potentially via modulation of the microbiome—enhance the synthesis of pro-resolving mediators in the gut.

Substances involved in this link: Frankincense (Boswellia) · Turmeric and Curcumin · Humic acid complexes · Omega-3 fatty acids

Implications and Open Questions

Hypothesis Inflammation does not end through mere inhibition but through active resolution—a process specifically promoted by natural compounds such as omega-3 fatty acids (via resolvins), curcumin (via NF-κB/COX-2), and boswellic acids (via 5-LOX). This chain demonstrates that these substances not only lower biomarkers like CRP or IL-6 but also improve clinical outcomes (joints, gut, skin). The critical factor is the switching of macrophages to an anti-inflammatory phenotype that enables tissue regeneration. The combination of inflammation inhibition and resolution may explain why these natural compounds are often more effective in chronic diseases (e.g., IBD, osteoarthritis) than classical COX inhibitors. It remains unclear whether humic acid complexes—potentially via binding to NF-κB or enhancing resolvin synthesis—support this process synergistically. If so, this would represent a paradigm shift: moving away from mere suppression toward the active resolution of inflammation.

To investigate: A randomised study would need to clarify whether the combination of omega-3 fatty acids with humic acid complexes enhances the synthesis of pro-resolving mediators (e.g., 17-HDHA, resolvin E1) in humans—measurable via plasma and tissue levels. In parallel, it should be examined whether this combination improves clinical endpoints (e.g., remission rates in IBD, pain scores in osteoarthritis) more effectively than the individual compounds. Additionally, it would be important to assess whether humic acid complexes inhibit NF-κB activity in immune cells—potentially by binding to the DNA-binding domain of the dimer. Classical COX inhibitors could serve as a control group to demonstrate that resolution involves more than mere suppression of inflammation.

Further links: All context pages · Interaction network · Gaps list